[Skip to Content]
[Skip to Content Landing]
Medical News & Perspectives
February 6, 2008

Phase 3 Trials Suggest Ways to Improve Current Hematologic Cancer Therapies

JAMA. 2008;299(5):510-512. doi:10.1001/jama.299.5.510

Atlanta—Therapeutic advances in recent years have beaten back and even defeated hematologic cancers in many patients, yet oncologists note that poor prognoses and cancer death rates remain significant. At the 49th Annual Meeting of the American Society of Hematology, held here in December, researchers discussed some of the latest efforts to advance the treatment of hematologic cancers, including Hodgkin and non-Hodgkin lymphomas, leukemia, and multiple myeloma.

First Page Preview View Large
First page PDF preview
First page PDF preview